ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 446

Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients

Cesar Vargas-Serafin1, Luis Aguilar-Lozano1, Jorge Padilla-Ibarra1, Carlos Sandoval-Castro1, Jose Dionisio Castillo-Ortiz1, Jorge Morales-Torres2, Claudia Hernandez2 and Cesar Ramos-Remus1, 1Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, 2Rheumatology, Hospital Aranda de la Parra, Leon, Mexico

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: , ,

Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Although there is much discussion regarding when to initiate a biological agent in rheumatoid arthritis (RA) patients, data on when to stop these agents is scant. Disease activity outcomes after the ending of an industry sponsored clinical trials may provide useful information regarding the duration of drug-free remission for a given biological agent. The aim of this study was to assess the length of remission and rate of relapse of disease activity after ending the open label, long-term extension study (5 yrs) using tocilizumab in RA patients enrolled in the OPTION1 trial.

Methods: Patients who no longer received tocilizumab because of the ending of the extension study (5 yrs) of the OPTION trial were analyzed. All patients were: a) in remission (DAS28 < 2.6, 0 swollen joints) at the time of the last tocilizumab administration (week 260), b) followed thereafter every 8 weeks until relapse (≥ 1 swollen joints), c) on a stable methotrexate dose during the follow-up.

Results: Forty-five patients were analyzed, 87% females with a mean age of 52 yrs and a mean disease duration of 14 yrs. During the first 12 months of follow-up, 26 (58%) patients maintained remission, and at the last visit (17 months) 17 (38%) patients continued in remission. Relapses occurred in 28 (62%) patients: 14 (50%) of them during the first three months after the last tocilizumab administration. No variables were identified to predict length of remission.

Conclusion: Long-term clinical remission is possible in a substantial number of RA patients after suspension of tocilizumab. Additional data are required to support recommendations for discontinuing a biological agent after achieving remission. These recommendations would impact in patients’ safety and the economic burden imposed by these treatments.

Reference: 1Smolen JS et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo controlled, randomized trial. Lancet 2008;371:989–97.

Disclosure:

C. Vargas-Serafin,
None;

L. Aguilar-Lozano,
None;

J. Padilla-Ibarra,
None;

C. Sandoval-Castro,
None;

J. D. Castillo-Ortiz,
None;

J. Morales-Torres,
None;

C. Hernandez,
None;

C. Ramos-Remus,
None.

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-remission-and-rate-of-relapse-after-tocilizumab-withdrawal-in-rheumatoid-arthritis-patients/